Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression
- PMID: 18792977
- DOI: 10.1002/ajmg.a.32294
Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression
Abstract
In mucopolysaccharidosis I, deficiency of alpha-L-iduronidase can cause spinal cord compression (SCC) due to storage of glycosaminoglycans (GAGs) within the cervical meninges. As intravenous enzyme replacement therapy (ERT) is not likely to provide enzyme across the blood-brain barrier, standard treatment for this complication is usually surgical, which has a high morbidity and mortality risk. We report on the use of intrathecal (IT) laronidase in a MPS I patient with SCC who refused the surgical treatment. Assessments were performed at baseline, with clinical and biochemical evaluations, 4-extremity somatosensory evoked potentials, 12 min walk test and MRI studies of the CNS. Changes on these parameters were evaluated after 4 IT infusions of laronidase administered monthly via lumbar puncture. To our knowledge, this was the first MPS patient who received IT ERT. No major adverse events were observed. There were no clinically significant changes in serum chemistries. CSF GAG results revealed pretreatment values slightly above normal standards: 13.3 mg/L (NV < 12 mg/L) which after IT laronidase infusions were within normal levels (10.3 mg/L). 12MWT presented a 14% improvement, with better performance on stability and gait control. Maximum voluntary ventilation showed 55.6% improvement considering the percentage of predicted (26.7% at baseline compared to 41.9%); Maximum Inspiration Pressure improved 36.6% of predicted (26.8% at baseline to 36.7%); Pulmonary diffusion improved 17.6% of predicted %. In conclusion, although the improvement observed in this case with IT laronidase should be confirmed in further patients, this procedure seems to be a safe treatment for SCC in MPS I.
Copyright 2008 Wiley-Liss, Inc.
Similar articles
-
Safety of laronidase delivered into the spinal canal for treatment of cervical stenosis in mucopolysaccharidosis I.Mol Genet Metab. 2015 Sep-Oct;116(1-2):69-74. doi: 10.1016/j.ymgme.2015.07.005. Epub 2015 Jul 26. Mol Genet Metab. 2015. PMID: 26260077 Free PMC article. Clinical Trial.
-
Intrathecal administration of recombinant human N-acetylgalactosamine 4-sulfatase to a MPS VI patient with pachymeningitis cervicalis.Mol Genet Metab. 2010 Apr;99(4):346-50. doi: 10.1016/j.ymgme.2009.11.008. Epub 2009 Dec 5. Mol Genet Metab. 2010. PMID: 20036175
-
Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type I.Mol Genet Metab. 2010 Oct-Nov;101(2-3):115-22. doi: 10.1016/j.ymgme.2010.06.020. Epub 2010 Jul 23. Mol Genet Metab. 2010. PMID: 20655780 Free PMC article.
-
Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.Cochrane Database Syst Rev. 2016 Apr 1;4:CD009354. doi: 10.1002/14651858.CD009354.pub4. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2019 Jun 18;6:CD009354. doi: 10.1002/14651858.CD009354.pub5. PMID: 27033167 Updated. Review.
-
Mucopolysaccharidosis type I.Pediatr Endocrinol Rev. 2014 Sep;12 Suppl 1:102-6. Pediatr Endocrinol Rev. 2014. PMID: 25345091 Review.
Cited by
-
A rapid and sensitive method for measuring N-acetylglucosaminidase activity in cultured cells.PLoS One. 2013 Jun 28;8(6):e68060. doi: 10.1371/journal.pone.0068060. Print 2013. PLoS One. 2013. PMID: 23840811 Free PMC article.
-
Safety evaluation of chronic intrathecal administration of heparan N-sulfatase in juvenile cynomolgus monkeys.Drug Deliv Transl Res. 2012 Jun;2(3):187-200. doi: 10.1007/s13346-011-0043-1. Drug Deliv Transl Res. 2012. PMID: 25786866
-
Brain and spinal MR imaging findings in mucopolysaccharidoses: a review.AJNR Am J Neuroradiol. 2013 Jan;34(1):5-13. doi: 10.3174/ajnr.A2832. Epub 2012 Jul 12. AJNR Am J Neuroradiol. 2013. PMID: 22790241 Free PMC article. Review.
-
Safety of laronidase delivered into the spinal canal for treatment of cervical stenosis in mucopolysaccharidosis I.Mol Genet Metab. 2015 Sep-Oct;116(1-2):69-74. doi: 10.1016/j.ymgme.2015.07.005. Epub 2015 Jul 26. Mol Genet Metab. 2015. PMID: 26260077 Free PMC article. Clinical Trial.
-
Gene therapy for neurologic manifestations of mucopolysaccharidoses.Expert Opin Drug Deliv. 2015 Feb;12(2):283-96. doi: 10.1517/17425247.2015.966682. Epub 2014 Dec 16. Expert Opin Drug Deliv. 2015. PMID: 25510418 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials